<div class="headers"><div>Fig. 7 (a) FEV1 AUC0–3 and trough FEV1 responses, (b) SGRQ total score and (c) TDI focal score: treatment comparisons at 12 weeks for T + O 5/5 μg versus T 5 μg and versus placebo in patients who were receiving/ not receiving ICS treatment at baseline</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Fig. 7 (a) FEV1 AUC0–3 and trough FEV1 responses, (b) SGRQ total score and (c) TDI focal score: treatment comparisons at 12 weeks for T + O 5/5 μg versus T 5 μg and versus placebo in patients who were receiving/ not receiving ICS treatment at baseline</p></td>
</tr>
</tbody>
</table>
